Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gossamer Bio (GOSS) Shares Outstanding (Weighted Average) (2022 - 2025)

Gossamer Bio's Shares Outstanding (Weighted Average) history spans 4 years, with the latest figure at $228.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 1.01% year-over-year to $228.5 million; the TTM value through Dec 2025 reached $228.5 million, up 1.01%, while the annual FY2025 figure was $228.5 million, 603.84% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $228.5 million in Q4 2025 per GOSS's latest filing, up from $227.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $228.5 million in Q4 2025 to a low of $32.5 million in Q3 2023.
  • Average Shares Outstanding (Weighted Average) over 4 years is $157.4 million, with a median of $189.2 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): crashed 64.39% in 2023, then surged 597.15% in 2024.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $84.6 million in 2022, then skyrocketed by 80.46% to $152.6 million in 2023, then skyrocketed by 48.23% to $226.2 million in 2024, then rose by 1.01% to $228.5 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's Shares Outstanding (Weighted Average) are $228.5 million (Q4 2025), $227.4 million (Q3 2025), and $227.3 million (Q2 2025).